nonselective beta blocker
Phase 3Small molecule
nonselective beta blocker is one of 31 small molecule programs targeting Osteoporosis. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
37 competitors in Osteoporosis
#DrugCompanyPhaseTrials
1Zometa
PfizerApproved
Forteo
AAlmaject
Approved
Fosamax
OOrganon and Co
Approved
Evista
Eli LillyApproved
Rocaltrol
Jazz PharmaceuticalsApproved
Sensipar
AmgenApproved
Estrace
Novo NordiskApproved
Calciferol
Jazz PharmaceuticalsApproved
Achromycin V
WWyeth-Lederle Vaccines
Approved
Epsom Salt
FFresenius Kabi USA, LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for nonselective beta blocker. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSherief Abd-Elsalam